UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 13.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 170,615 shares of the biotechnology company’s stock after selling 27,597 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.81% of Enanta Pharmaceuticals worth $1,768,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in Enanta Pharmaceuticals by 18.9% in the third quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 7,839 shares in the last quarter. Valence8 US LP bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $207,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $122,000. Quest Partners LLC lifted its position in shares of Enanta Pharmaceuticals by 65.0% during the 3rd quarter. Quest Partners LLC now owns 19,123 shares of the biotechnology company’s stock worth $198,000 after buying an additional 7,535 shares during the period. Finally, US Bancorp DE lifted its position in shares of Enanta Pharmaceuticals by 4,933.7% during the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ENTA. Robert W. Baird dropped their price objective on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.50.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the completion of the sale, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at approximately $6,461,202.28. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.64% of the stock is owned by company insiders.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $6.31 on Tuesday. The business’s fifty day moving average is $10.22 and its two-hundred day moving average is $11.92. The firm has a market cap of $133.73 million, a P/E ratio of -1.15 and a beta of 0.49. Enanta Pharmaceuticals, Inc. has a 52 week low of $5.84 and a 52 week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same period in the prior year, the firm earned ($1.33) earnings per share. The business’s quarterly revenue was down 22.8% compared to the same quarter last year. On average, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.73 earnings per share for the current year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.